Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8529805 | European Journal of Pharmacology | 2017 | 20 Pages |
Abstract
Atherosclerosis is a leading cause of death worldwide. It is a complex chronic inflammatory disease involving interactions between vascular, circulating and immune cells. B cells play an important role in chronic inflammation producing antibodies and regulating T and natural killer (NKT) cell activation. The role of B cells in atherosclerosis is complex, with atherogenic and protective roles assigned for distinct B cell subsets. Drugs that deplete B cells or modulate their functions are now used in the treatment of various autoimmune diseases in humans. Here, we briefly review the roles of B cell subsets in atherogenesis, and emphasize the potential impact of B cell targeted therapies on the cardiovascular risk of treated patients. Developing more B cell subset-specific therapies would lead to more effective treatments with enhanced safety profile.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Meritxell Nus, Dimitrios Tsiantoulas, Ziad Mallat,